Amoy Diagnostics Hits Day High with Strong 5.73% Intraday Surge

Amoy Diagnostics Co., Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has shown significant activity today, gaining 5.73% on August 13, 2026. The stock reached an intraday high of CNY 20.00, marking a notable performance against the backdrop of a -0.5% decline in the China Shanghai Composite index. Over the past week, Amoy Diagnostics has outperformed the broader market with a 13.05% increase, while its one-month performance stands at 13.18%. However, the stock has faced challenges over the longer term, with a -17.91% return over the past year and a substantial -76.95% decline over the last five years. Key financial metrics indicate a return on equity (ROE) of 17.08% and a price-to-book ratio of 3.62, suggesting a fair valuation. The company also boasts a dividend yield of 2.40%. Despite recent gains, Amoy Diagnostics has underperformed the China Shanghai Composite in various time frames, highlighting the mixed performance landscape for the stock.